Plain-English translation of NCT06603792 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new treatment called neurofeedback (EEG-NF) to help people with diabetes who have painful nerve damage. During neurofeedback, you wear sensors on your scalp that show your brain activity on a computer screen in real time, and you learn to control that activity to reduce pain. The goal is to see whether this brain-training approach works better than a placebo version.
Many people with diabetes develop painful nerve damage, but current pain medications often don't work well and can cause serious side effects. This new treatment offers a drug-free option by teaching your brain to manage pain signals on its own, which could help fill an important gap in care.
If you qualify, you will be randomly assigned to either the real brain-training group or a placebo group. You will attend 10 sessions where sensors are placed on your scalp to read your brain activity, and a computer screen gives you real-time feedback to help you learn to control your brain patterns. Some participants in Brazil will also have brain scans (MRI) to show how the treatment works. The study will track how your pain changes throughout the treatment period.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Denmark
Phase
Safety & dosing
Sponsor
University of Southern Denmark
Collaborators
European Foundation for the Study of Diabetes, Region of Southern Denmark
Enrollment target
~54 participants
Started
September 2024
Primary completion
January 2026
Age range
18 Years – 82 Years
Last updated on clinicaltrials.gov in September 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Francois Pouwer, Professor
University of Southern Denmark